SWAT/PESHAWAR/ISLAMABAD: Rescuers retrieved nine bodies from the Swat River on Friday after at least 17 tourists were swept ...

Pfizer PFE announced that the phase III BASIS study evaluating its anti-TFPI inhibitor Hympavzi (marstacimab) for treating ...

M3GAN 2.0 takes that tradition to terrifying new extremes, particularly thanks to the unforgettable presence of Amelia. As ...

You’re a kid. You catch a few seconds of something strange on TV. Those few seconds have a way, sometimes, of paying a call decades later. It happened to author, critic and film curator Michael ...

Justin Tucker, one of the best kickers in NFL history, suspended for 10 weeks after 16 women said he was sexually ...

Pfizer has reported positive topline outcomes from the multicentre, open-label Phase III BASIS trial of Hympavzi (marstacimab ...

The Democrat will be the first woman and one of fewer than 20 Minnesotans accorded the honor. She will lie in state with her ...

Topline data were announced from a phase 3 trial evaluating marstacimab for adults and adolescents living with hemophilia A or B with inhibitors.

Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and ...

Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its ...

Pfizer said a late-stage study of its Hympavzi hemophilia drug met its key goals in patients with the blood-clotting disorder who have inhibitors that can render some treatments ineffective.

Primary and secondary end points were demonstrated in a phase 3 trial of subcutaneous marstacimab as treatment for patients ...